SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, and the Members of the European Concerted Action on Sjögren's syndrome. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999; 42: 176572.
  • 2
    Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand J Rheumatol 2000; 29: 3418.
  • 3
    Van der Reijden WA, Vissink A, Veerman EC, Nieuw Amerongen AV. Treatment of oral dryness related complaints (xerostomia) in Sjogren's syndrome. Ann Rheum Dis 1999; 58: 46574.
  • 4
    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 23542.
  • 5
    Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 27415.
  • 6
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 282533.
  • 7
    Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti–B cell therapy [review]. Arthritis Rheum 2003; 48: 148492.
  • 8
    Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004; 58: 299309.
  • 9
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 257281.
  • 10
    Pijpe J, Kalk WW, Vissink A. Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjogren's syndrome. J Rheumatol 2003; 30: 2067.
  • 11
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 12
    Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 218895.
  • 13
    Aalberse RC, Dieges PH, Knul-Bretovla V, Vooren P, Aalbers M, van Leeuwen J. IgG4 as a blocking antibody. In: HalpernGM, editor. Clinical reviews in allergy. vol. I. New York: Elsevier Biomedical; 1983. p. 289302.
  • 14
    Kalk WW, Vissink A, Stegenga B, Bootsma H, Nieuw Amerongen AV, Kallenberg CG. Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjogren's syndrome. Ann Rheum Dis 2002; 61: 13744.
  • 15
    Mandel ID, Baurmash H. Sialochemistry in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1976; 41: 1827.
  • 16
    Bijsterveld O. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol 1969; 82: 104.
  • 17
    Kalk WW, Mansour K, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, et al. Oral and ocular manifestations in Sjogren's syndrome. J Rheumatol 2002; 29: 92430.
  • 18
    Smets EM, Garssen B, Bonke B, de Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 31525.
  • 19
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 20
    Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, et al. Fatigue in primary Sjogren's syndrome. Ann Rheum Dis 1998; 57: 2915.
  • 21
    Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjogren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000; 29: 208.
  • 22
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al, and the NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 124453.
  • 23
    Gottenberg J, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 91320.
  • 24
    Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab mono-therapy in a patient with Sjogren's syndrome and associated MALT-lymphoma. Ann Rheum Dis 2005; 64: 95860.
  • 25
    Shih WJ, Ghesani N, Hongming Z, Alavi A, Schusper S, Mozley D. F-18 FDG positron emission tomography demonstrates resolution of non- Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002; 27: 1423.
  • 26
    Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003; 49: 3948.
  • 27
    Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 2004; 43: 10503.
  • 28
    Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjogren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005; 32: 1439.
  • 29
    Oxholm P. Primary Sjogren's syndrome: clinical and laboratory markers of disease activity. Semin Arthritis Rheum 1992; 2: 11426.
  • 30
    Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, et al. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000; 43: 90816.
  • 31
    Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16: 24653.
  • 32
    Vissink A, Panders AK, Nauta JM, Ligeon EE, Nikkels PG, Kallenberg CG. Applicability of saliva as a diagnostic fluid in Sjogren's syndrome. Ann N Y Acad Sci 1993; 694: 3259.
  • 33
    Pederson AM, Reibel J, Nordgarden H, Bergem HO, Jensen JL, Nauntofte B. Primary Sjogren's syndrome: salivary gland function and clinical oral findings. Oral Dis 1999; 5: 12838.
  • 34
    D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine–human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2003; 44: 17178.
  • 35
    Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment [letter]. Ann Oncol 2003; 14: 1792.
  • 36
    Herishanu Y. Rituximab-induced serum sickness [letter]. Am J Hematol 2002; 70: 329.
  • 37
    Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 221724.
  • 38
    Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 26737.
  • 39
    Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 8838.
  • 40
    Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 1993; 11: 14956.
  • 41
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 25809.
  • 42
    Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001; 44: 23715.